RTI Surgical (NASDAQ:RTIX) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of RTI Surgical (NASDAQ:RTIX) from a sell rating to a hold rating in a research report released on Saturday morning, Zacks.com reports.

According to Zacks, “RTI Surgical Inc. is a surgical implant company. Its implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures. RTI Surgical Inc., formerly known as RTI Biologics, Inc., is headquartered in Alachua, Fla. “

A number of other equities analysts also recently commented on RTIX. ValuEngine downgraded RTI Surgical from a buy rating to a hold rating in a report on Thursday, April 2nd. Cantor Fitzgerald assumed coverage on RTI Surgical in a report on Monday, June 15th. They set a buy rating and a $5.00 target price for the company. Finally, BidaskClub downgraded RTI Surgical from a hold rating to a sell rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. RTI Surgical has an average rating of Hold and a consensus target price of $4.08.

Shares of RTIX stock opened at $3.18 on Friday. RTI Surgical has a fifty-two week low of $1.46 and a fifty-two week high of $5.40. The stock has a 50 day moving average price of $2.72 and a two-hundred day moving average price of $2.94. The company has a market capitalization of $212.61 million, a P/E ratio of -1.09 and a beta of 2.11.

RTI Surgical (NASDAQ:RTIX) last announced its quarterly earnings data on Monday, June 8th. The medical equipment provider reported ($0.16) earnings per share for the quarter. RTI Surgical had a negative net margin of 68.63% and a positive return on equity of 1.75%. The company had revenue of $80.21 million during the quarter. On average, equities analysts forecast that RTI Surgical will post -0.3 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Krensavage Asset Management LLC grew its stake in shares of RTI Surgical by 11.0% in the first quarter. Krensavage Asset Management LLC now owns 4,027,772 shares of the medical equipment provider’s stock worth $6,887,000 after acquiring an additional 398,809 shares during the last quarter. Advisor Group Holdings Inc. purchased a new stake in shares of RTI Surgical in the first quarter worth $45,000. Squarepoint Ops LLC purchased a new stake in shares of RTI Surgical in the first quarter worth $224,000. Jane Street Group LLC purchased a new stake in shares of RTI Surgical in the first quarter worth $47,000. Finally, Invesco Ltd. grew its stake in shares of RTI Surgical by 418.1% in the first quarter. Invesco Ltd. now owns 90,320 shares of the medical equipment provider’s stock worth $154,000 after acquiring an additional 72,886 shares during the last quarter. 63.61% of the stock is currently owned by hedge funds and other institutional investors.

RTI Surgical Company Profile

RTI Surgical Holdings, Inc, a surgical implant company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.

Featured Article: How do taxes affect a CDs total return?

Get a free copy of the Zacks research report on RTI Surgical (RTIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.